In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Aytu BioScience Inc (AYTU), with a price target of $10. The company’s shares opened today at $2.06.
Byrnes observed:
“We anticipate these finding will prove to bolster Natesto® visibility as an alternative and support Aytu’s marketing efforts.”
According to TipRanks.com, Byrnes is a 1-star analyst with an average return of -0.4% and a 29.6% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Adamas Pharmaceuticals, Flexion Therapeutics, and Heron Therapeutics.
The the analyst consensus on Aytu BioScience Inc is currently a Hold rating.
See today’s analyst top recommended stocks >>
Based on Aytu BioScience Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $4.66 million. In comparison, last year the company had a GAAP net loss of $3.67 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aytu BioScience, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of novel products for urology. It operates through the Aytu, and Aytu Women’s Health segments. The Aytu segment consists of core male urology products.
